title: Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine.
abstract: The authors present a case of a patient with dementia with mood symptoms and multiple neurological manifestations of fragile X-associated tremor/ataxia syndrome (FXTAS). Despite a gradually deteriorating neurological course, he was managed for 2 years with combination therapy of donepezil and venlafaxine, which resulted in improvement and relative stabilization of his psychiatric status. Psychiatrists are hereby alerted to the description of a novel dementia syndrome that may respond to pharmacological intervention commonly used for other dementias.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, University of California, Davis, Medical Center, 2230 Stockton Blvd., Sacramento, 95817, USA. james.bourgeois@ucdmc.ucdavis.edu
authors.forename: James A
authors.initials: JA
authors.lastname: Bourgeois
authors.forename: Faraz
authors.initials: F
authors.lastname: Farzin
authors.forename: James A
authors.initials: JA
authors.lastname: Brunberg
authors.forename: Flora
authors.initials: F
authors.lastname: Tassone
authors.forename: Paul
authors.initials: P
authors.lastname: Hagerman
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.forename: David
authors.initials: D
authors.lastname: Hessl
authors.forename: Randi
authors.initials: R
authors.lastname: Hagerman
mesh_terms: D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001259:Ataxia / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D001284:Atrophy; D001921:Brain / Q000473:pathology; D003511:Cyclohexanols / Q000627:therapeutic use*; D003704:Dementia / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D004292:Dominance, Cerebral / Q000502:physiology; D000077265:Donepezil; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics*; D005600:Fragile X Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D006580:Genetic Carrier Screening; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007189:Indans / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008609:Mental Status Schedule; D019964:Mood Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D009460:Neurologic Examination; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D014202:Tremor / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D018911:Trinucleotide Repeats; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000077265:Donepezil; D051860:Fragile X Messenger Ribonucleoprotein 1; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000069470:Venlafaxine Hydrochloride; C497683:FMR1 protein, human